ع
Eli Lilly and Company announced in a press release distributed via Zawya that it appointed Tayllit Aherdan as vice president and general manager to lead its business in the United Arab Emirates, Qatar and Kuwait. The announcement, issued earlier this week, coincides with Gulf states intensifying healthcare agendas that stress innovation alongside prevention, early intervention and improved access to cutting-edge therapies. Aherdan will direct the company’s regional strategy to bolster its contributions to these national priorities while advancing Lilly’s goal of developing medicines that support longer, healthier lives.
In the statement Aherdan said “The Gulf is demonstrating extraordinary ambition in how it is reimagining the future of healthcare, and Lilly has an important role to play in supporting that journey.” She continued that the company’s opportunity goes beyond delivering scientific advances to encompass partnerships with governments, healthcare leaders and other stakeholders that convert innovation into tangible patient benefits. Aherdan added she looked forward to expanding on Lilly’s established presence through targeted investments in talent and collaboration that align with systems oriented toward improved outcomes and sustained value.
Aherdan enters the role with more than two decades of biopharmaceutical leadership that has spanned North Africa, the Middle East, Asia, Europe and additional territories beyond the United States. She most recently held the position of chief marketing officer at Lilly China, where she directed a comprehensive digital overhaul of commercial operations inside one of the globe’s most dynamic healthcare environments. Earlier she served as vice president for international oncology, guiding pre-launch planning and market introductions for new therapies across more than 100 countries throughout Latin America, Europe, the Middle East, Africa and Asia.
A Research and Markets assessment found the GCC healthcare innovation market reached 121.9 billion dollars in 2025 and is projected to expand to 170.5 billion dollars by 2030 at a compound annual growth rate of 5.9 percent. Separate analysis cited in regional reporting places overall healthcare spending on track to hit 159 billion dollars by 2029 while advancing at nearly 8 percent each year. These trajectories reflect sustained government investment in modern infrastructure, digital tools and preventive care across the UAE, Qatar and Kuwait.
Lilly’s release indicated that under Aherdan the company will maintain momentum in cardiometabolic health, neuroscience, oncology and immunology. The firm intends to partner with local stakeholders to enhance patient access, promote scientific dialogue and foster innovation models that remain viable over the long term. Such efforts build directly on the company’s established footprint in the Gulf.
According to a study published in the National Library of Medicine drawing on World Health Organization figures, healthcare spending as a share of gross domestic product ranges from 2.6 percent in Qatar to 5.3 percent in Kuwait, with public funds accounting for between 64 percent and 90 percent of total expenditure depending on the country. The PMC review noted that universal coverage for citizens coexists with varying degrees of private insurance and out-of-pocket costs that differ by jurisdiction. Lilly’s background material, included in the release, underscored its 150-year track record of advancing therapies for diabetes care, obesity management, Alzheimer’s disease, immune-system conditions and difficult-to-treat cancers.
